Holland ML, Allen JD, Arnold JC (2008) Interaction of plant cannabinoids with the multidrug

transporter ABCC1 (MRP1). Eur J Pharmacol 591:128–131

Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al (2002) International Union

of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):

161–202

Hu DL, Zhu G, Mori F, Omoe K, Okada M, Wakabayashi K (2007) Staphylococcal enterotoxin

induces emesis through increasing serotonin release in intestine and it is downregulated by

cannabinoid receptor 1. Cell Microbiol 9:2267–2277

Iuvone T, Esposito G, Esposito R (2004) Neuroprotective effect of cannabidiol, a non-psychoactive

component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem

89:134–141

Jan TR, Farraj AK, Harkema JR, Kaminski NE (2003) Attenuation of the ovalbumin-induced

allergic airway response by cannabinoid treatment in A/J mice. Toxicol Appl Pharmacol 188(1):

24–35

Kandel DB (1984) Marihuana users in young adulthood. Arch Gen Psychiatry 41(2):200–209

Khan MI, Sobocińska AA, Brodaczewska KK, Zielniok K, Gajewska M, Kieda C et al (2018)

Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle

arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma. BMC Cancer 18(1):

583

Klein TW, Newton C, Zhu W et al (1995) Delta9-tetrahydrocannabinol, cytokines, and immunity to

legionella pneumophila. Proc Exp Biol Med 209(3):205–212

Klein TW, Newton C, Friedman H (1998) Cannabinoid receptors and immunity. Immunol Today

19(8):373–381

Klein TW, Lane B, Newton CA et al (2000) The cannabinoid system and cytokine network. Proc

Soc Exp Biol Med 225(1):1–8

Kogan NM, Mechoulam R (2007) Cannabinoids in health and disease. Dialogues Clin Neurosci

9(4):413–430

Li HL, Lin H (1974) An archaeological and historical account of cannabis in China. Econ Bot 28(4):

437–447

Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874

Luszczki

JJ,

Czuczwar

P,

Cioczek-Czuczwar

A,

Czuczwar

SJ

(2006)

Arachidonyl-2-

0-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticon-

vulsant action of valproate in the mouse maximal electroshock-induced seizure model. Eur J

Pharmacol 547:65–74

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B (2017) The different

mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 7(3):339–348

Martin-Fontecha M, Eiwegger T, Jartti T, Rueda-Zubiaurre A, Tiringer K, Stepanow J (2014) The

expression of cannabinoid receptor is significantly increased in atopic patients. J Allergy Clin

Immunol 133(3):926–929.e2

Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D et al (2004) Antitumor

effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol

Exp Ther 308:838–845

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid

receptor and functional expression of the cloned cDNA. Nature 346:561–564

McAllister SD, Chan C, Taft RJ, Luu T, Abood ME, Moore DH et al (2005) Cannabinoids

selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme

cells. J Neurooncol 74:31–40

Mechoulam R, Gaoni YJ (1965) A total synthesis of delta 1 tetrahydrocannabinol, the active

constituents of hashish. Am Chem Soc 87:3273–3275

Melvin LS, Johnson MR (1987) Structure-activity relationships of tricyclic and nonclassical

bicyclic cannabinoids. NIDA Res Monogr 79:31–47

Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P et al (2008) Cannabinoids in

pancreatic cancer: correlation with survival and pain. Int J Cancer 122(4):742–750

12

Emerging Role of Cannabinoid System Modulators in Treatment of Cancer

199